Peter Wuerl

1.9k total citations · 1 hit paper
8 papers, 1.5k citations indexed

About

Peter Wuerl is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Peter Wuerl has authored 8 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Peter Wuerl's work include Epigenetics and DNA Methylation (3 papers), Cancer-related Molecular Pathways (3 papers) and Sarcoma Diagnosis and Treatment (2 papers). Peter Wuerl is often cited by papers focused on Epigenetics and DNA Methylation (3 papers), Cancer-related Molecular Pathways (3 papers) and Sarcoma Diagnosis and Treatment (2 papers). Peter Wuerl collaborates with scholars based in Germany, United States and United Kingdom. Peter Wuerl's co-authors include Helge Täubert, Gareth L. Bond, Frank Bartel, Elisabeth E. Bond, Harlan Robins, Arnold J. Levine, Wenwei Hu, Stuart Lutzker, Nicoleta C. Arva and Louise C. Strong and has published in prestigious journals such as Cell, Cancer Research and Clinical Cancer Research.

In The Last Decade

Peter Wuerl

8 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

2004 1.0k citations Gareth L. Bond, Wenwei Hu et al. Cell profile →

Peers

Countries citing papers authored by Peter Wuerl

Since Specialization

Citations

This map shows the geographic impact of Peter Wuerl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Wuerl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Wuerl more than expected).

Fields of papers citing papers by Peter Wuerl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Wuerl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Wuerl. The network helps show where Peter Wuerl may publish in the future.

Co-authorship network of co-authors of Peter Wuerl

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Wuerl. A scholar is included among the top collaborators of Peter Wuerl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Wuerl. Peter Wuerl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants 2019 ·JAMA Surgery ·Christos Dimitrakopoulos, Bart Vrugt, Renata Flury, Peter Schraml, Uwe Knippschild, Peter J. Wild, Simon P. Hoerstrup, Doris Henne‐Bruns, Peter Wuerl, Rolf Graf, Stefan Breitenstein, Gareth L. Bond, Niko Beerenwinkel, Lukasz F. Grochola	21
2	Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer 2012 ·Cancer Research ·Kristiaan Lenos, Anna M. Grawenda, Kirsten Lodder, Marieke L. Kuijjer, Amina F.A.S. Teunisse, Emmanouela Repapi, Lukasz F. Grochola, Frank Bartel, Pancras C.W. Hogendoorn, Peter Wuerl, Helge Täubert, Anne‐Marie Cleton-Jansen, Gareth L. Bond, Aart G. Jochemsen	51
3	Long-Term Outcome after Total Parathyroidectomy for the Management of Secondary Hyperparathyroidism 2009 ·Nephron Clinical Practice ·Sylvia Stracke, Frieder Keller, Gerald Steinbach, Doris Henne‐Bruns, Peter Wuerl	43
4	A Three-Gene Signature for Outcome in Soft Tissue Sarcoma 2009 ·Clinical Cancer Research ·Andreas-Claudius Hoffmann, Kathleen D. Danenberg, Helge Täubert, Peter V. Danenberg, Peter Wuerl	37
5	p16 Expression Differentiates High-Risk Gastrointestinal Stromal Tumor and Predicts Poor Outcome 2008 ·Neoplasia ·(unknown), Sebastian Wolf, (unknown), (unknown), Markus Juchems, Peter Wuerl, Doris Henne‐Bruns, Uwe Knippschild, Cornelia Hasel, Klaus Kramer	30
6	Esophageal Perforation: Principles of Diagnosis and Surgical Management 2006 ·Surgery Today ·Markus Huber‐Lang, Doris Henne‐Bruns, Bernd Schmitz, Peter Wuerl	67
7	MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner 2006 ·Cancer Research ·Gareth L. Bond, Kim M. Hirshfield, Tomas Kirchhoff, (unknown), Elisabeth E. Bond, Harlan Robins, Frank Bartel, Helge Täubert, Peter Wuerl, William N. Hait, Deborah Toppmeyer, Kenneth Offit, Arnold J. Levine	242
8	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans breakdown → 2004 ·Cell ·Gareth L. Bond, Wenwei Hu, Elisabeth E. Bond, Harlan Robins, Stuart Lutzker, Nicoleta C. Arva, Jill Bargonetti, Frank Bartel, Helge Täubert, Peter Wuerl, Kenan Onel, Linwah Yip, Shih-Jen Hwang, Louise C. Strong, Guillermina Lozano, Arnold J. Levine	1026

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact